Latest Breaking News On - Elisa buffington - Page 1 : comparemela.com

Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Dan patersonRyan porterElisa buffingtonRaf and mek programInternational conference on molecularSecura bio incCorporate communicationsExchange commissionCompany annual report on formDrug administrationChugai pharmaceutical co ltdMore complete vertical blockadeImprove outcomesResponses observedPre treated patientsEnrollment ongoing

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesCity ofSusana banerjeeRyan porterDan patersonRachel grishamElisa buffingtonResearch lead for the gynaecology unitSecura bio incFoundation incEuropean society of gynaecological oncologyCorporate communicationsNational cancer instituteInstitute of cancer researchEuropean network for gynaecological oncological trial

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progres

Plan to Submit Application for Accelerated Approval for Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in H1 2024Expects to Begin Enrollment in Phase 3 Confirmatory Trial, RAMP 301, of Avutometinib and Defactinib in LGSOC in Q4 2023Presented Additional Patient Subgroup Data for the.

United statesRyan porterElisa buffingtonDan patersonPancreatic cancer action network panChugai pharmaceutical co ltdDevelopment collaborationFoundation incDrug administrationHead of regulatory affairsCorporate communicationsPatient impactWorld ovarian cancer coalitionPatient impact advisory committeeInternational conference on molecularExchange commission

Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low

Planned Subgroup Analysis of RAMP 201 Data Showed Combination Demonstrated Robust Efficacy in Recurrent LGSOC Regardless of Number and Class of Prior Therapies Including After Poor Response to Prior TherapyLate-Breaking Abstract Featured as an Oral Presentation during a Plenary Session at the Annual Global Meeting o.

Soult ukpyolsiSouth koreaUnited statesRyan porterElisa buffingtonRachel grishamCompany annual report on formSecura bio incChugai pharmaceutical co ltdExchange commissionDrug administrationRaf and mek programCorporate communicationsPlanned subgroup analysisShowed combination demonstrated robust efficacyPrior therapies including after poor response

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Elisa buffingtonDan calkinsRyan porterCorporate communicationsVerastem incVerastem oncologyNasdaq listing rule